Search Weight Loss Topics:




Sep 25

Dr. Shore on the Objective of the HERO Trial in Advanced Prostate Cancer – OncLive

Testosterone Comments Off on Dr. Shore on the Objective of the HERO Trial in Advanced Prostate Cancer – OncLive

Neal D. Shore, MD, FACS, discusses the objective of the phase 3 HERO trial in advanced prostate cancer.

Neal D. Shore, MD, FACS, medical director of the Carolina Urologic Research Center, discusses the objective of the phase 3 HERO trial in advanced prostate cancer.

The objective of the HERO trial was to compare the oral, once-daily gonadotropin-releasing hormone agonist relugolix (Relumina) with 3-monthleuprolide (Lupron) in patients with advanced prostate cancer, says Shore. The primary end point of the study was testosterone (T)-suppression through 48 weeks. Results showed noninferiority,as well as superiority with regard to T-suppression with relugolix over leuprolide acetate.

The patients included in this trial had prostate-specific antigen (PSA) or biochemical relapse; relapsed after surgery, radiation, or both;or hadnewly diagnosed metastatic disease or high-risk localized disease. The demographics were well balanced in terms of age, race, and geographic region, as well as clinical characteristics regarding their baseline PSAs, as well as their testosterone levels, concludes Shore.

See original here:
Dr. Shore on the Objective of the HERO Trial in Advanced Prostate Cancer - OncLive

Related Posts

    Your Full Name

    Your Email

    Your Phone Number

    Select your age (30+ only)

    Select Your US State

    Program Choice

    Confirm over 30 years old

    Yes

    Confirm that you resident in USA

    Yes

    This is a Serious Inquiry

    Yes

    Message:



    matomo tracker